Opportunity Information: Apply for RFA CA 24 024
The National Cancer Institute (NCI), through its Division of Cancer Prevention (DCP), is soliciting applications for performance sites within the Cancer Prevention Clinical Trials Network (CP-CTNet) under the UG1 cooperative agreement mechanism, with a clinical trial required. The purpose of this opportunity is to support the real-world infrastructure and operational capacity needed to plan and conduct early-phase (phase 0 through phase 2) cancer prevention clinical trials. In practical terms, CP-CTNet is positioned as DCP's primary national platform for moving promising cancer preventive interventions from early clinical testing toward broader development, by running trials that focus on biological activity and credible intermediate signals rather than large, definitive endpoint trials.
The trials conducted through CP-CTNet are designed to evaluate the biologic effects of preventive interventions and to identify clinically meaningful correlates that can indicate whether an intervention is on a plausible path to preventing cancer. These studies often emphasize mechanistic outcomes, biomarker modulation, pharmacodynamic effects, dosing and feasibility questions, and other early indicators that help determine whether an intervention should advance. The network is expected to develop and run multiple prevention trials across different organ sites, reflecting the reality that cancer risk and prevention strategies vary by tissue type, exposure, and underlying biology. The program also explicitly anticipates collaborative studies across the network, meaning sites are not just running isolated trials but are participating in a coordinated set of prevention research activities.
This specific NOFO is aimed at the CP-CTNet "sites" that will do the hands-on work of planning and performing the clinical trials. Because it is a cooperative agreement (UG1), the relationship between the awardees and NCI is intended to be more collaborative than a typical grant, with substantial federal scientific and/or programmatic involvement expected during the planning and conduct of the trials. The emphasis is on building and sustaining the clinical research capability to execute prevention trials efficiently and consistently within a national network structure.
Eligibility is broad and includes many common public, academic, nonprofit, and private-sector applicant types, such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses. The announcement also highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it clearly states that non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply; however, foreign components are allowed as defined in the NIH Grants Policy Statement, which typically means specific, well-justified elements of the work may be carried out by foreign collaborators under NIH rules even though the applicant organization must be domestic.
Key administrative details include the funding opportunity title "Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)," funding opportunity number RFA-CA-24-024, and agency name National Institutes of Health (NIH) with NCI as the sponsoring institute. The opportunity is categorized as discretionary and uses the cooperative agreement funding instrument. The activity category is listed under education and health, and the CFDA numbers associated with this program are 93.393 and 93.399. The original closing date is 2024-10-31, and the opportunity was created on 2024-08-12. The provided source information does not specify an award ceiling or the expected number of awards, indicating applicants should consult the full NOFO text for budget limits, project period details, and the anticipated scale of the site awards.Apply for RFA CA 24 024
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
- This funding opportunity was created on 2024-08-12.
- Applicants must submit their applications by 2024-10-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity solicits applications for performance sites within the Cancer Prevention Clinical Trials Network (CP-CTNet) under the UG1 cooperative agreement mechanism, with a clinical trial required. The network is sponsored by the National Cancer Institute (NCI) through its Division of Cancer Prevention (DCP).
What is the official title of the opportunity?
The funding opportunity title is "Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)."
What is the funding opportunity number (NOFO number)?
The funding opportunity number is RFA-CA-24-024.
Which agency and institute are sponsoring this opportunity?
The agency is the National Institutes of Health (NIH), and the sponsoring institute is the National Cancer Institute (NCI).
What does CP-CTNet stand for, and what is its role?
CP-CTNet stands for the Cancer Prevention Clinical Trials Network. It is positioned as DCP's primary national platform for moving promising cancer preventive interventions from early clinical testing toward broader development, primarily by running early-phase prevention trials that focus on biological activity and credible intermediate signals rather than large definitive endpoint trials.
What is the main purpose of this opportunity?
The purpose is to support the real-world infrastructure and operational capacity needed to plan and conduct early-phase (phase 0 through phase 2) cancer prevention clinical trials as part of a national network.
What kind of award mechanism is used?
This opportunity uses a UG1 cooperative agreement mechanism.
What does it mean that this is a cooperative agreement (UG1)?
A cooperative agreement indicates that the relationship between awardees and NCI is intended to be more collaborative than a typical grant, with substantial federal scientific and/or programmatic involvement expected during the planning and conduct of the trials.
Is a clinical trial required for this award?
Yes. The opportunity is explicitly described as "UG1 Clinical Trial Required," and the supported work centers on planning and conducting clinical trials within CP-CTNet.
What phases of clinical trials does CP-CTNet support?
CP-CTNet supports early-phase cancer prevention clinical trials, specifically phase 0 through phase 2.
What types of outcomes do these trials emphasize?
Trials are designed to evaluate biologic effects of preventive interventions and identify clinically meaningful correlates that can indicate whether an intervention plausibly may prevent cancer. Emphasis commonly includes mechanistic outcomes, biomarker modulation, pharmacodynamic effects, dosing questions, feasibility, and other early indicators rather than large definitive endpoint outcomes.
Are these trials intended to be large, definitive endpoint trials?
No. CP-CTNet is described as focusing on biological activity and credible intermediate signals instead of large, definitive endpoint trials.
What kinds of interventions are expected to be studied?
The opportunity focuses on cancer preventive interventions that are promising enough to undergo early clinical testing to assess biologic activity and intermediate signals. Specific intervention categories are not listed in the provided description.
What is meant by "credible intermediate signals" in this context?
In this program context, credible intermediate signals refer to early indicators such as mechanistic outcomes, biomarker changes, and pharmacodynamic effects that help determine whether an intervention appears to be on a plausible path toward preventing cancer.
What is meant by "performance sites" or "CP-CTNet sites"?
This NOFO is aimed at the CP-CTNet sites that do the hands-on work of planning and performing the clinical trials, including maintaining the operational capability to execute prevention trials efficiently and consistently within the national network.
Will sites run only one trial, or multiple trials?
The network is expected to develop and run multiple prevention trials across different organ sites, and the program anticipates coordinated activities across the network.
Do trials need to cover different organ sites?
The network is expected to develop and run multiple prevention trials across different organ sites, reflecting that cancer risk and prevention strategies vary by tissue type, exposure, and underlying biology.
Is collaboration across the network expected?
Yes. The program explicitly anticipates collaborative studies across the network, meaning sites are expected to participate in coordinated prevention research activities rather than only isolated trials.
What type of support is the opportunity intended to provide to sites?
The emphasis is on building and sustaining clinical research infrastructure and operational capacity to plan and conduct early-phase cancer prevention trials within a national network.
Who is eligible to apply?
Eligibility is broad and includes: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses.
Are minority-serving institutions and community-based organizations eligible?
Yes. The announcement highlights eligibility for categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, and regional organizations.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are listed among eligible applicant categories.
Are non-U.S. (non-domestic) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply.
Can a U.S. organization include non-U.S. components in its application?
No. Non-domestic components of U.S. organizations are not eligible to apply.
Are foreign components allowed at all?
Yes. Foreign components are allowed as defined in the NIH Grants Policy Statement, meaning specific, well-justified elements of the work may be carried out by foreign collaborators under NIH rules, even though the applicant organization must be domestic.
What is the program category or type of opportunity?
The opportunity is categorized as discretionary and uses a cooperative agreement funding instrument.
What activity category is this opportunity listed under?
The activity category is listed under education and health.
What CFDA numbers are associated with this program?
The CFDA numbers associated with this program are 93.393 and 93.399.
When was this opportunity created?
The opportunity was created on 2024-08-12.
What is the closing date (application due date) listed in the provided information?
The original closing date listed is 2024-10-31.
Does the provided information specify the award ceiling?
No. The provided source information does not specify an award ceiling.
Does the provided information specify the expected number of awards?
No. The provided source information does not specify the expected number of awards.
Where should applicants look for budget limits, project period details, and award scale?
The provided information indicates applicants should consult the full NOFO text for budget limits, project period details, and the anticipated scale of the site awards.
What is the overall goal of CP-CTNet trials in the development pipeline?
The network is intended to help move promising cancer preventive interventions from early clinical testing toward broader development by generating biologic and intermediate evidence that can inform whether an intervention should advance.
Browse more opportunities from the same category: Education, Health
Next opportunity: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Previous opportunity: Strengthening High Quality Laboratory Services Scale-Up for HIV Diagnosis, Care, Treatment and Monitoring in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 24 024
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 24 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required) Apply for RFA CA 24 025 Funding Number: RFA CA 24 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required) Apply for RFA CA 24 028 Funding Number: RFA CA 24 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed) Apply for PAR 24 269 Funding Number: PAR 24 269 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) Apply for RFA DA 26 002 Funding Number: RFA DA 26 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) Apply for RFA DA 26 001 Funding Number: RFA DA 26 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) Apply for RFA DA 26 008 Funding Number: RFA DA 26 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed) Apply for RFA DA 26 007 Funding Number: RFA DA 26 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional) Apply for RFA CA 25 011 Funding Number: RFA CA 25 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional) Apply for RFA CA 25 012 Funding Number: RFA CA 25 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 24 274 Funding Number: PAR 24 274 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 25 063 Funding Number: RFA DA 25 063 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional) Apply for PAR 24 273 Funding Number: PAR 24 273 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NLM Information Resource Grants to Reduce Health Disparities and Promote Health Equity (G08 Clinical Trial Not Allowed) Apply for PAR 24 281 Funding Number: PAR 24 281 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) Apply for PAR 25 043 Funding Number: PAR 25 043 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) Apply for PAR 25 044 Funding Number: PAR 25 044 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) Apply for PAR 24 277 Funding Number: PAR 24 277 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) Apply for PAR 24 291 Funding Number: PAR 24 291 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 073 Funding Number: RFA DA 25 073 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) Apply for PAR 24 297 Funding Number: PAR 24 297 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) Apply for PAR 24 298 Funding Number: PAR 24 298 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 24 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.